BioNTech is set to shutter multiple sites in Germany, impacting about 1,800 jobs, after efforts to find buyers fell through.

Eli Lilly’s portfolio of weight loss and diabetes medications have become a dominant force in the market—but access to the ...

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...

The commercial environment facing today's life sciences sales teams looks very different from the one many organizations were ...

Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...

Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...

From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater ...

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...

GSK showed a “totally unacceptable” lack of transparency in its interactions wi | GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...

In just over a month, the FDA has cleared not one, but two treatments for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic condition that causes soft tissues to turn to bone. | Mirum ...

Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, ...